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Abstract
You have recently heard reports that synthetic colloids may be
associated with renal failure and other morbidities in certain popu-
lations of critically ill patients. You have been asked by the hospital
chief of staff whether there should be a suspension of the use of
synthetic colloids until further information is available. You need to
make a decision.
Statement for debate
‘Until further data are available, synthetic colloids should not
be used in critically ill patients with sepsis.’
Introduction
Colloid solutions are commonly used to replenish or maintain
intravascular volume status in a variety of clinical settings.
Human albumin is a natural and relatively safe colloid [1] but
its high cost has driven a search for safe synthetic alter-
natives. Three types of synthetic colloids are currently used
worldwide: (a) hydroxyethyl starches (HESs), (b) gelatins, and
(c) dextrans.
Hydroxyethyl starches
HESs are modified natural polymers of amylopectin. HES
solutions are distinguished by (a) their molecular weight
(MW), (b) their molar substitution ratio, and (c) their C2/C6
substitution ratio. These characteristics determine the rate of
metabolism of the HES molecules, which in turn affects both
the half-life and the side effects of the solution.
The average MW of the HES molecules in the solution
(measured in kilodaltons) is inversely correlated with colloidal
activity because HES solutions are supplied in weight-based
concentrations (usually 6% or 10%). Low-MW solutions con-
tain more molecules of HES for a given concentration and
thus have a higher oncotic pressure, but they have a shorter
half-life in vivo because they are more quickly broken down
by serum amylase to 50-kDa molecules that can be excreted
in the urine. Solutions are typically divided into three weight
categories: high MW (approximately 450 kDa) (for example,
Hespan®), medium MW (200 to 260 kDa) (for example,
HemoHES® and Pentaspan®), and low MW (70 to 130 kDa)
(for example, Voluven®).
To slow metabolism by amylase, HES molecules have
hydroxyethyl radical groups substituted onto individual
glucose units. The degree of hydroxyethyl substitution is
expressed by the molar substitution ratio, which is simply a
ratio of the number of substituted glucose molecules to the
total number of glucose molecules. Highly substituted HES
solutions have a ratio of 0.6 to 0.7 and are metabolized
slowly. Less substituted HES solutions have a ratio of 0.4 to
0.5 and are metabolized quickly. Finally, the point of
attachment of the hydroxyethyl group is also important.
Hydroxyethyl groups attached at the C2 position on the
glucose ring slow metabolism more than those attached at
the C6 or C3 position. Thus, a high C2/C6 ratio (>8) slows
metabolism more than a low C2/C6 ratio (<8).
Gelatins
Gelatins are polypeptides derived from bovine collagen.
Modern gelatin preparations are chemically modified in
various ways to reduce viscosity while maintaining their
oncotic effect. Gelatins are smaller molecules than HESs
(approximately 35 kDa) and therefore are more rapidly broken
down and eliminated. However, there is no published dose
limitation for gelatins as there are for HES and dextrans [2].
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Dextrans
Dextrans are a polysaccharide mixture derived from the
bacterium Leuconostoc mesenteroides, typically used in solu-
tions of either 40- or 70-kDa molecules. Dextrans have a high
water-binding capacity and are very effective for reducing
blood viscosity [3].
Pro: There is no justification for using
synthetic colloids in patients with septic shock
Investigators have long known about the potential risks of
synthetic colloids, including renal failure, coagulopathy, ana-
phylactoid reactions, reticuloendothelial dysfunction, hepatic
dysfunction, and severe pruritus [4]. As described in the
section above, the synthetic colloids represent a group of
products with different properties, and studies of one product
may not be representative of the group as a whole. However,
numerous investigators have concluded that synthetic
colloids are safe (or superior to albumin or crystalloids) on the
basis of small studies using surrogate, biochemical, or
hemodynamic endpoints and often very brief follow-up [5-15].
On the other hand, two large prospective randomized trials
with lengthy follow-up and hard endpoints have now shown
that HES is associated with a significantly increased risk of
acute renal failure (ARF), coagulopathy, and possibly mortality
in patients with septic shock. Schortgen and colleagues [16]
randomly assigned 129 patients to receive either HES
200/0.62 or 3% gelatin for intravascular volume expansion
and followed them for 34 days. They found that the HES
group had a significantly higher incidence of ARF (defined as
a twofold increase in creatinine, 42% versus 23%;
P = 0.028), and in a multivariate analysis, the use of HES was
associated with an odds ratio of 2.57 for ARF. The investi-
gators were careful to respect the dose limitations recom-
mended by the manufacturer, giving an average of 14 mL/kg
(range of 10 to 26) on day 1 and less than 20 mL/kg for the
next 3 days. HES was not administered after the fourth day.
In the more recent VISEP (Efficacy of Volume Substitution
and Insulin Therapy in Severe Sepsis) study, Brunkhorst and
colleagues [17] randomly assigned 537 patients with severe
sepsis or septic shock to receive either HES 200/0.5 or
Ringer lactate as part of a 96-hour protocol to maintain a
central venous pressure of greater than 8 mm Hg, a central
venous O2 saturation of greater than 70%, and a mean
arterial pressure of greater than 70 mm Hg. Again, patients in
the HES group had a higher incidence of renal failure
requiring dialysis (31.0% versus 18.8%; P = 0.001). The
protocol specified a daily limit of 20 mL/kg of HES [17] but
this was exceeded in approximately 35% of patients in the
HES group, mostly on day 1. When the investigators looked
only at the patients who had received less than 20 mL/kg of
study fluid daily, there was still a significantly higher incidence
of renal failure requiring dialysis. The investigators also identi-
fied a clear dose effect of HES. Higher cumulative doses of
HES were correlated with both a higher 90-day mortality rate
and a higher incidence of renal failure requiring dialysis. This
dose effect was not seen in the Ringer lactate group.
While other investigators did not detect a significant increase
in the incidence of ARF or mortality, this may have been due
to their shorter follow-up (that is, less than 5 days). Data from
the latter two studies suggest that differences in the
incidence of ARF and mortality may not become apparent
until 5 and 30 days, respectively [18].
HES administration is also associated with a deterioration in
renal function in patients undergoing cardiovascular surgery
[9,19] and kidney donation [20]. The mechanism of renal
injury from HES is unclear, but possible explanations include
osmotic injury [20], ischemic injury from hyperviscosity [21],
or injury related to significant HES uptake by the reticulo-
endothelial system in the kidney [22,23].
Some have argued that the increased incidence of renal failure
can be attributed to either the long half-life or crystalloid
solvent of some HES solutions, suggesting that newer low-
MW HES [24] or ‘balanced’ solvents [25] might be safe.
However, studies of low-MW HES in cardiac surgery patients
show evidence of impaired postoperative glomerular filtration
rate [9] and elevated serum markers of renal function [19], and
patients who received low-MW HES during abdominal
surgery showed greater elevations in α1-microglobulin levels
than those who received medium-MW HES [10]. Furthermore,
a study comparing a ‘balanced’ and ‘unbalanced’ HES
solution in patients undergoing abdominal surgery demon-
strated no difference, with no renal dysfunction or coagulo-
pathy in either group [6]. Thus, the advantages of low-MW
HES or ‘balanced’ solvents are certainly not proven [6].
There are no large, published, randomized controlled trials of
dextrans or gelatins in patients with sepsis, but the data from
other clinical settings are not encouraging [26]. In patients
undergoing cardiac surgery, gelatin shows an effect similar to
HES on markers of renal dysfunction [19] and is associated
with higher rates of ARF than crystalloid [27] and HES [28].
Studies of dextrans also show an association with renal
failure [29,30]. There is no evidence to suggest that gelatins
and dextrans are associated with a lower risk of renal
dysfunction than crystalloid.
High- and medium-MW HES preparations cause coagulo-
pathy primarily by reducing levels of factor VIII and von
Willebrand factor and by interfering with platelet function
[24,31]. In the VISEP study, patients in the HES group
developed worse coagulopathy, as demonstrated by a higher
Sequential Organ Failure Assessment (SOFA) coagulation
score, and a greater need for transfusion of packed red blood
cells compared with the crystalloid group (median of 6 units
versus 4 units) [17]. Low-MW HES preparations do not
appear to show the same effects on factor VIII and von
Willebrand factor [24]. Again, fewer studies have examinedthe bleeding risks associated with dextrans and gelatins but
both appear to be associated with impaired coagulation and
increased bleeding risk [2,32].
Synthetic colloids are effective volume expanders but their
use in septic shock cannot be justified in light of the adverse
effects. Even ‘safe’ doses are associated with significant
morbidity; newer generation colloids appear to cause adverse
reactions similar to the older colloids, and ‘balanced’ solvent
solutions are unproven. Until a large randomized trial with
hard endpoints and adequate follow-up demonstrates that
one of these solutions is safe and effective, we must
conclude that the only safe dose for synthetic colloids is zero.
Con: Synthetic colloids should be used but
not abused
A policy to ban synthetic colloids in the treatment of critically
ill patients with septic shock is certainly not supported by the
current data. The argument revolves largely around two
randomized controlled trials [16,17], both of which used a
clinically unlikely regimen: in the HES arm, the starch
appeared to be administered as the sole intravenous fluid for
many patients (up to a daily maximum level). In the real-life
situation, colloids are usually used as intermittent boluses in
conjunction with concomitantly administered crystalloid fluids.
A study arm in which colloid was the predominant
intravenous fluid provided is not generalizable to usual clinical
practice. Furthermore, the dose of colloid administered in the
VISEP study was far higher than that used clinically, with a
median dose of 2.4 L (and a maximum dose of 13 L!) on the
first day of therapy [33]. In clinical practice, it is uncommon to
administer near the maximal dosage. A further confounding
issue is the fact that, in the VISEP study, 26.6% of patients in
the crystalloid arm received some form of colloid, either the
study HES or another colloid product [17].
Studies of HES used as an adjunct to crystalloid fluid
therapy, to facilitate reaching hemodynamic targets, have
shown benefit. A study of septic and trauma patients, in
which HES was given with crystalloid (administered in a
volume ratio of approximately 1:3.5), showed clear benefits in
terms of hemodynamic improvement and oxygen delivery [5].
Long-term renal function was not assessed in this study. The
absence of an association of HES with renal failure in usual
clinical practice was demonstrated in a large European
observational study of over 3,000 patients [34]. One third of
these patients (1,075 patients) received HES with a median
dose of 555 mL per day (median total dose of 1,000 mL in
2 days). Although the incidence of renal failure was higher in
this group, there was no association between HES and
dialysis in a multivariable model. Patients who received HES
were also older, were more likely to be surgical patients, and
had a higher severity of illness.
Others have reported a lack of association between the use
of HES and renal failure in clinical use, in which HES is
combined with crystalloid therapy [35]. In a study of 62
patients undergoing abdominal aortic surgery, a reduced
incidence of renal injury was noted in patients randomly
assigned to received one of two HES products (HES
200/0.62 or HES 130/0.4) compared with gelatin [36]. All
patients received concomitant infusions of normal saline,
amounting to approximately twice the volume of colloid. Only
one patient in each HES group required renal replacement
therapy (4.8%) compared with three in the gelatin group
(15%). A recent study evaluated renal effects in 33 patients
with pre-existing mild renal dysfunction who were randomly
assigned to receive 6% HES (130/0.4) or gelatin (in addition
to at least 1.5 L/day crystalloid) for perioperative volume
replacement for abdominal aortic surgery [37]. Five patients
(15%) in the HES arm developed severe renal impairment
that was not different from the gelatin-treated arm, although
this does not exclude the possibility that both the HES and
gelatin caused some renal dysfunction.
Furthermore, a comprehensive ban on all synthetic colloids
would overlook the important differences between older and
newer synthetic colloids. Neither of the above-mentioned
randomized trials studied one of the new low-MW HES
solutions. No study has demonstrated a link between low-
MW HES solutions and an increased need for dialysis, and
while high-MW HES solutions are clearly associated with
coagulopathy, the low-MW HES solutions are not [24,38,39].
A study of renal function in cadaveric renal transplant
recipients compared donors resuscitated with a 200/0.6
hetastarch and those resuscitated with a new-generation
130/0.4 product in a retrospective matched paired study
[40]. The group that received the 130/0.4 hetastarch had a
significantly reduced incidence of delayed graft failure (22%
versus 33%). Furthermore, animal studies suggest that HES
solutions containing a more physiologically ‘balanced’ solvent
(for example, Ringer lactate) might cause less renal impair-
ment and coagulopathy than one containing normal or hyper-
tonic saline [25]. One study in patients undergoing abdominal
surgery found that a ‘balanced’ HES solution produced a
smaller acid-base disturbance than an ‘unbalanced’ solution [6].
The results of Schortgen and colleagues [16] and Brunkhorst
and colleagues [17] should warn clinicians not to exceed the
recommended daily dose of synthetic colloid and to use a
balanced approach to fluid resuscitation that includes crystal-
loid solutions. They should not serve as the basis of a
comprehensive ban on synthetic colloids in any patient
population.
Conclusions
We cannot support a comprehensive ban on synthetic
colloids on the basis of only two trials [16,17] but these two
trials represent the best evidence currently available (in terms
of randomization, endpoints, and follow-up). Since both
suggested that the use of medium-MW HES solutions is
associated with harm in patients with septic shock, these
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Synthetic colloids are potent volume expanders but they may
be harmful and are probably unnecessary for most patients.
The current data should alert clinicians to potential concerns
with the administration of high volumes of HES, particularly
the medium-MW HES solutions favoured in many parts of the
world. Synthetic colloids definitely should not be used as the
sole source of intravenous fluid in critically ill patients, and
ordering physicians should be aware of the potential adverse
effects, including allergic reactions, renal dysfunction, and
coagulopathy. Maximum dosages for these products should
be made known to all users and strictly monitored whenever
possible. Newer-generation low-MW HES solutions or
balanced crystalloid solvents may be safer but this has never
been conclusively demonstrated.
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